Arbutus Biopharma (ABUS) Accounts Payables (2016 - 2025)
Historic Accounts Payables for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to $4.7 million.
- Arbutus Biopharma's Accounts Payables fell 3832.18% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 3832.18%. This contributed to the annual value of $7.6 million for FY2024, which is 2635.58% down from last year.
- Arbutus Biopharma's Accounts Payables amounted to $4.7 million in Q3 2025, which was down 3832.18% from $4.5 million recorded in Q2 2025.
- Arbutus Biopharma's Accounts Payables' 5-year high stood at $16.0 million during Q4 2022, with a 5-year trough of $4.5 million in Q2 2025.
- Moreover, its 5-year median value for Accounts Payables was $9.7 million (2023), whereas its average is $9.4 million.
- As far as peak fluctuations go, Arbutus Biopharma's Accounts Payables surged by 7007.01% in 2021, and later tumbled by 5941.66% in 2025.
- Quarter analysis of 5 years shows Arbutus Biopharma's Accounts Payables stood at $10.8 million in 2021, then skyrocketed by 47.9% to $16.0 million in 2022, then plummeted by 35.92% to $10.3 million in 2023, then fell by 26.36% to $7.6 million in 2024, then crashed by 38.48% to $4.7 million in 2025.
- Its Accounts Payables was $4.7 million in Q3 2025, compared to $4.5 million in Q2 2025 and $12.1 million in Q1 2025.